Conjugates of Anticancer Agents and Polymers: Advantages of Macromolecular Therapeutics in Vivo

Bioconjugate Chemistry

Volumn 3, Issue 5, 1992, Pages 351-362

  Maeda, Hiroshi ^a   Miyamoto, Yoichi ^a   Seymour, Len W ^b,c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KEELE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; IMMUNOTOXIN; POLYMER;

AMINO ACID SEQUENCE; HUMAN; MACROMOLECULE; METABOLISM; MOLECULAR GENETICS; NEOPLASM; REVIEW; VASCULARIZATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; IMMUNOTOXINS; MACROMOLECULAR SUBSTANCES; MOLECULAR SEQUENCE DATA; NEOPLASMS; POLYMERS;

EID: 0026926609     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc00017a001     Document Type: Article

References (111)

1. Maeda, H. Matsumoto, T. Konno, T., Iwai, K. and Ueda, M. (1984) Tailor-making of protein drugs by polymer conjugation for tumor targeting. A brief review on smancs. J. Protein Chem. 3, 181-193.
2. Maeda, H. (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 6, 181-202.
3. Maeda, H., and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210.
4. Seymour, L. (1992) Passive tumour-targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9, 135-187.
5. Duncan, R. (1992) Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs (in press).
6. Shelanski, H. A., and Shelanski, M. V. (1956) PVP-iodine: history, toxicity and therapeutic uses. J. Intern. Coll. Surgeons 25, 727-734.
7. Takakura, Y., Takagi, A. Hashida, M., and Sezaki, H. (1987) Disposition and tumor localization of mitomycin C-Dextran conjugates in mice. Pharm. Res. 4, 293-300.
8. Maeda, H., Matsumoto, Y. Oda, T., and Sasamoto, K. (1986) Cancer selective macromolecular therapeusis: tailoring of an antitumor protein drug. Protein Tailoring for Food and Medical Uses (R. E. Feeny and J. R. Whitaker, Eds.), 353-382, Marcel Dekker Inc., New York.
9. Ogino, T., Inoue, M. Ando, Y. Arai, M. Maeda, H., and Morino, Y. (1988) Chemical modification of superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin. Int. J. Pept. Protein Res. 32, 153-159.
10. Kobayashi, A., Oda, T., and Maeda, H. (1988) Protein binding of macromolecular anticancer agent SMANCS: Characterization of poly(styrene-comaleic acid) derivatives as an albumin binding ligand. J. Bioact. Compat. Polym. 3, 319-328.
11. Matsumura, Y_, and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and antitumor agent smancs. Cancer Res. 46, 6387-6392.
12. Seymour, L. W., Duncan, R., Strohalm, J., and Kopecek, J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mater. Res. 21, 1341-1358.
13. Matsumoto, M.H.K. Yamamoto, T., Kamata, R., and Maeda, H. (1986) Enhancement of vascular permeability upon serratial infection: Activation of Hageman factor-kallikrein-kinin cascade. Kinin IV, partB (L. B. Greenbaum and H. S. Margolius, Ed.) pp 71-78 (AEMB 198B), Plenum Press, New York.
14. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A. Harrey, V. S., and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid. Science 219, 983-985.
15. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109.
16. Leung, D. W., Cachianes, G., Kuang, W.-J. Goeddel, D. V., and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
17. Keck, P. J. Hauser, S. D. Krivi, G. Sanzo, K. Warren, T. Feder, J., and Connolly, D. T. (1989) Vascular permeability factor and endothelial cell mitogen related to PDGF. Science 246, 1309-1312.
18. Senger, D. R., Perruzzi, C. A. Feder, J. and Dvorak, H.-F., A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cells. Cancer Res. 46, 5629-5632.
19. Senger, D. R. Connolly, D. T. Van de Water, L. Feder, J., and Dvorak, H. F. (1990) Purification and NH2-terminal amino acid sequences of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50, 1774-1778.
20. Brock, T. A., Dvorak, H. F. and Senger, D. (1991) Tumor-secreted vascular permeability factor increases cytosolic calcium and von Willebrand factor release in human endothelial cells. Am. J. Pathol. 138, 213-221.
21. Olander, J. V., Connolly, D. T., and DeLarco, J. E. (1991) Specific binding of vascular permeability factor to endothelial cells. Biochem. Biophys. Res. Commun. 175, 68-76.
22. Maeda, H., Matsumura, Y., and Kato, H. (1988) Purifìcation and identification of [hydroxyprolyl3] -bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263, 16051-16056.
23. Matsumura, Y. Kimura, M. Yamamoto, T. and Maeda, H. (1988) Involvement of kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79, 1327-1334.
24. Matsumura, Y., Maruo, K. Kimura, M., Yamamoto, T. Konno, T., and Maeda, H. (1991) Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn, J. Cancer Res. 82, 732-741.
25. Matsumura, Y. Maeda, H. and Kato, H. (1990) Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: Analysis by HPLC. Agents Actions 29, 172-180.
26. Fleck, A. Hawker, F. Wallace, P. I. Raines, G., Trotter, J. Ledingham, I. McA., and Caiman, K. C. (1985) Increased vascular permeability: A major cause of hypoalbuminemia in disease and injury. Lancet Apr 6, 781-784.
27. Ettinghausen, S. E., Puri, R. J. and Rosenberg, S. A. (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J. Natl. Cancer Inst. 80, 177-187.
28. Iwai, K., Maeda, H., and Konno, T. (1984) Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2114-2121.
29. Iwai, K., Maeda, H., Konno, T., Matsumura, Y, Yamashita, R., Yamasaki, K. Hirayama, S. and Miyauchi, Y. (1987) Tumor targeting by arterial administration of lipids: Rabbit model with VX-2 carcinoma in the liver. Anticancer Res. 7, 321-328.
30. Konno, T. Maeda, H. Iwai, K. Maki, S. Tashiro, S. Uchida, M., and Miyauchi, Y. (1984) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54, 2367-2374.
31. Maki, S. Konno, T., and Maeda, H. (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer. 56, 751-757.
32. Konno, T., Maeda, H., Tashiro, S., Maki, S. Morinaga, T., Mochinaga, M., Hiraoka, T., and Yokoyama, I. (1983) Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report. Eur. J. Cancer Clin. Oncol. 19, 1053-1065.
33. Coutice, F. C. (1963) The origin of lipoprotein in lymph. Lymph and the Lymphatic System. (Meyersen, H. S., Chairman) pp 89-126, C. C. Thomas, Springfield, IL.
34. Suzuki, M., Hori, M.H.K. Abe, I., Saito, S. and Sato, H. (1981) A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67, 663-669.
35. Hori, K., Suzuki, M., Abe, I., Saito, S. and Sato, H_ (1985) Increase in tumor vascular area due to increased blood flow by angiotensin II in rats. J. Natl. Cancer Inst. 74, 453-459.
36. Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A. Tsurumi, H., Takashima, K. and Maeda, H. (1992) Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn. J. Cancer Res. 83, 240-243.
37. Sela, M. (1969) Antigenicity: Some molecular aspects. Science 166, 1365-1374.
38. Habeeb, A. F. S. A. Cassidy, H. G. and Singer, S. F. (1958) Molecular structural effects produced in proteins by reaction with succinic anhydride, Biochim. Biophys. Acta 29, 587-593.
39. Jones, V. E. and Leskowitz, S. (1965) Role of the carrier in development of delayed sensitivity to the azophenyl-azonate group. Nature 207, 596-597.
40. Rajnavolgyi, E., Hudecz, F., Mezo, G., Szekerke, M., and Gergely, J. (1986) Isotope distribution and fine specificity of the antibody response or inbred mouse strain to four compounds belonging to a new group of synthetic branched polypeptide. Mol. Immunol. 23, 27-37.
41. Hunter, R. L. and Bennet, B. (1984) The adjuvant activity of nonionic block polymer surfactants. Antibody formation and inflammation related to the structure of triblock and octablock copolymer. J, Immunol. 133, 3167-3175.
42. Kamisaki, Y., Wada, H., Yagura, H., Matsushima, A., and Inada, Y. (1981) Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypoly(ethylene glycol). J. Pharmacol. Exp, Ther. 216, 410-414.
43. Abuchowski, A., Es, T.-V., Palczuk, N. C. and Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578-3581.
44. Abuchowski, A. McCoy, J. R. Palczuk, N. C. Es, T. V. and Davis, F. F. (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
45. Maeda, H. (1981) Neocarzinostatin in cancer chemotherapy—A review. Anticancer Res. 1, 175-186.
46. Yatamoto, S., Maeda, H., Matsumoto, T., and Ogata, J. Experimental and clinical studies on the formation of antibody to neocarzinostatin, a new protein antibiotic. Cancer Treat, Rep. 62, 2063-2070.
47. Takakura, T. Kaneko, Y. Fujita, T., Hashida, M., Maeda, H., and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I. Synthesis and characterization. J. Pharm. Sci. 78, 117-121.
48. Takakura, Y., Fujita, T. Hashida, M., Maeda, H. and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II. Biophar-maceutical and pharmacological properties. J. Pharm. Sci. 78, 219-222.
49. Kimura, M., Matsumura, Y., Miyauchi, Y., and Maeda, H. A new tactic for the treatment of jaundice: An injectable polymer-conjugated bilirubin oxidase. Proc. Soc. Exp. Biol Med. 188, 364-369.
50. Hershfîeld, M.-S., Buckley, R. H., Greenberg, M. L. Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Martert, M. L., Kobayashi, R. H., Kobayashi, A. L., and Abuchowski, A. (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Engl. J. Med. 316, 589-596.
51. Katre, N. V., Knauf, M. J. and Laird, W.-J., (1987) Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in murine Meth A sarcoma model. Proc. Natl. Acad. Sci. 84t, 1487-1491.
52. Tabata, Y., Yamaoka, T., Ikada, Y. and Muramatsu, S. (1991) Effect of recombinant a-interferon-gelatin conjugate on in vivo murine tumor cell growth. Cancer Res. 51, 5532-5538.
53. Seymour, L. W., Flanagan, P. A., Al-Shamkhani, A., Subr, V., Ulbrich, M.H. Cassidy, J. A., and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumour-targeted drug delivery. Sei, Cancer Ther. 7, 59-73.
54. Kuromizu, M.H. Tsunasawa, S., Maeda, H., Abe, O., and Sakiyama, F. (1986) Reexamination of the primary structure of an antitumor protein, neocarzinostatin. Arch. Biochem. Biophys, 246, 199-205.
55. Kuromizu, M.H. Abe, O., and Maeda, H. (1991) Location of the disulfide bonds in the antitumor protein, neocarzinostatin. Arch. Biochem. Biphys, 286, 569-573.
56. Edo, K. Mizugaki, M., Koide, Y., Seto, H. Furihata, K. Otake, N., and Ishida, N. (1985) The structure of neocarzinostatin chromophore possessing a novel bicyclo-(7, 3, 0)-dodecadiyne system Tetrahedron Lett. 26, 331-334.
57. Maeda, H., Takeshita, J., and Kanamura, R. (1979) A lipophilic derivative of neocarzinostatin. Int. J. Pept. Protein Res. 14, 81-87.
58. Maeda, H., Ueda, M., Morinaga, T., and Matsumoto, T. Conjugation of poly(styrene-co-maleic acid) derivative to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties. J. Med. Chem. 29, 455-461.
59. Oda, T., Sato, F. Yamamoto, H., Akagi, M., and Maeda, H. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture. Anticancer Res. 9, 261-266.
60. Suzuki, F., Munakata, T., and Maeda, H. (1988) Interferon induction by SMANCS. Anticancer Res. 8, 97-104.
61. Oda, T., Morinaga, T., and Maeda, H. (1986) Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane. Proc. Soc. Exp. Biol Med. 181, 9-17.
62. Suzuki, F. Pollard, R. B., and Maeda, H. (1989) Stimulation of non-specific resistance to tumor in the mouse using a poly-(maleic acid-styrene) conjugated neocarzinostatin. Cancer ImmunoL Immunother. 30, 97-104.
63. Suzuki, F. Pollard, R. B. Uchimura, S. Munakata, T. and Maeda, H. (1990) Role of natural killer cells and macrophages in the non-specific resistance to tumors in mice stimulated with SMANCS. A polymer-conjugated derivative of neocarzinostatin. Cancer Res, 50, 3897-3904.
64. Seymour, L. (1991) Synthetic polymers with intrinsic anticancer activity. J. Bioact. Compat. Polym. 6, 178-216.
65. Hirayama, S. Sato, F. Oda, T., and Maeda, H. (1986) Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Jpn. J. Antibiot. 39, 815-822.
66. Konno, T., and Maeda, H. (1987) Targeting chemotherapy of hepatocellular carcinoma: arterial administration of smancs/ lipiodol. Neoplasm of the Liver (K. Okuda and K. G. Ishak, Ed.) Chapter 27, pp 343-352, Springer-Verlag, New York.
67. Kobayashi, M., Imai, K., Sugihara, S., Maeda, H., Konno, T., and Yamanaka, H. (1991) Tumor targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Urology. 37, 288-294.
68. Kimoto, A., Konno, T. Kawaguchi, T. Miyauchi, Y. and Maeda, H. (1992) Antitumor effects of SMANCS on rat mammary tumor induced by 7, 12 dimethylbenz[a]anthracene. Cancer Res. 52, 1013-1017.
69. Maeda, H. (1992) The tumor blood vessel as an ideal target for macromolecular anticancer agents. J. Controlled Release 19, 315-324.
70. Yamamoto, H. Miki, T. Oda, T., Hirano, T. Sera, Y. Akagi, M., and Maeda, H. (1990) Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinylether-maleic acid copolymer. Eur. J. Cancer 26, 253-260.
71. Maeda, H., Oda, T., Matsumura, Y., and Kimura, M. (1988) Improvement of pharmacological properties of protein drug by tailoring with synthetic polymers. J. Bioact. Compat. Polym. 3, 27-43.
72. Takahashi, T., Yamaguchi, T. Kitamura, M.H. Suzuyama, H. Honda, M. Yokota, Y. Kotanagi, Y. Takahashi, M. and Hashimoto, Y. (1988) Clinical application of monoclonal antibody drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 61, 25-33.
73. Takahashi, T. Yamaguchi, T. Kitamura, K. and Noguchi, A. Targeting chemotherapy using monoclonal antibody-drug conjugate for patients with digestive cancers. Proceeding of the Second Joint Meeting of the American Association for Cancer Research and the Japanese Cancer Association. “Molecular Oncology as a Basis for New Strategies in Cancer Therapy; February 10-14, 1992, Hawaii.
74. Kitamura, K. Takahashi, T. Yamaguchi, T. Noguchi, A., Noguchi, A., Takashima, K., Tsurumi, H., Inagake, M., Toyokuni, T., and Hakomori, S. (1991) Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 51, 4310-4315.
75. Suzuki, T., Sato, E., Goto, K., Katsurada, Y, Unno, M.H. and Takahashi, T. (1981) The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents. Chem. Pharm. Bull. 29, 844-848.
76. Kopecek, J., Rejmanova, P., Duncan, R., and Lloyd, J. B. Controlled release of drug model from N-(2-hydroxypropyl)methacrylamide copolymers. Ann. N.Y. Acad. Sci. 446, 93-104.
77. Rihova, B. Kopecek, J. Ulbrich, K. and Chytry, V. (1985) Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol. Chem” Supplement 9, 13-24.
78. Duncan, R. (1985) Biological effects of soluble synthetic polymers as drug carriers. CRC Crit, Rev, Ther. Drug Carrier Syst. 4t, 281-310.
79. Rihova, B. Ulbrich, K. Strohalm, J. Vetvicka, V. Bilej, M., Duncan, R., and Kopecek, J. (1989) Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect on haematopoietic stem cells in bone marrow in vivo and effect on mouse spleenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 10t, 335-342.
80. Flanagan, P. A., Kopeckova, P., Kopecek, J., and Duncan, R. (1989) Evaluation of antibody-N-(2-hydroxypropyl)-methacrylamide copolymer conjugates as targetable drug carriers. 1. Binding, pinocytic uptake and intracellular distribution of anti-transferrin receptor antibody-conjugates. Biochim. Biophys. Acta 993, 83-91.
81. Flanagan, P. A. Rihova, B. Subr, V. Kopecek, J. and Duncan, R. (1990) Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates measured in A/J and B10 mice. J. Bioact. Compat. Polym. 5, 151-166.
82. Duncan, R. Seymour, L. W.O'hare, M.H.B. Flanagan, P. A., Wedge, S. Ulbrich, M.H. Strohalm, J. Subr, V., Spreafico, F. Grandi, M. Ripamonti, M. Farao, M., Suarato, A. (1992) Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release 28, 123-132.
83. O'hare, M.H.B., Duncan, R., Strohalm, J., Kopeckova, P., Kopecek, J., and Ulbrich, K. Macromolecular prodrugs containing doxorubicin and melanocyte stimulating hormone in vitro and in vivo evaluation against murine melanoma. Br. J. Cancer (in press).
84. Duncan, R. Seymour, L. C. W. Scarlett, L. Lloyd, J. B. Rejmanova, P. and Kopecek, J. (1986) N-(2-hydroxypropyl)-methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration to rats. Biochim. Biophys. Acta 880, 62-71.
85. Seymour, L. W., Ulbrich, M.H. Strohalm, J., and Duncan, R. (1991) Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor. Br. J. Cancer 63, 859-866.
86. Stallard, S. Morrison, J. G. George, W. D., and Kaye, S. B. (1990) Distribution of doxorubicin to normal breast and tumor tissue in patients undergoing mastectomy. Cancer Chemother. Pharmacol. 25, 286-290.
87. Seymour, L. W., Ulbrich, M.H. Strohalm, J., Kopecek, J., and Duncan, R. (1990) Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39, 1125-1131.
88. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I., Lloyd, J. B., and Kopecek, J. (1988) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br. J. Cancer 57, 147-156.
89. Duncan, R., Hume, I. C., Kopeckova, P., Ulbrich, M.H. Strohalm, J., and Kopecek, J. (1989) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Controlled Release 10, 51-63.
90. Bernstein, A. Hurwitz, E. Maron, R. Arnon, R. Sela, M., and Wilchek, M. (1978) Higher antitumor efficacy of daunomycin when linked to dextran: In vivo and in vitro studies. J. Natl. Cancer Inst. 60, 379-384.
91. Fujita, H., Okamoto, M., and Takao, A. (1991) Pharmacokinetics of adriamycin-oxidized dextran conjugate (ADM-OXD) in experimental animals (in Japanese). Drug Delivery Syst. 6, 133-138.
92. Merigan, T. C., and Regelson, W. (1967) Interferon induction in man by a synthetic polyanion of defined composition. N. Engl. J. Med. 277, 1283-1287.
93. Hirano, T., Ohashi, S. Morimoto, S. Tsuda, K. Kobayashi, T., and Tsukagoshi, S. (1986) Synthesis of antitumor-active conjugates of adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride. Makromol. Chem. 187, 2815-2824.
94. Ohashi, S., Hirano, T., Morimoto, S., Kobayashi, T., Inaba, M., and Tsukagoshi, S. (1987) Antitumor activity of the conjugate of adriamycin with the copolymer of divinyl ether and maleic anhydride against M5076 fibrosarcoma. Procedings of 46th annual meeting of the Japanese Cancer Association. No. 1624. September, 1987, Tokyo (in Japanese).
95. Sezaki, H., and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1, 1-38.
96. Takakura, Y., Kitajima, M., Matsumoto, S. Hashida, M., and Sezaki, H. (1987) Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugte with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities. Int. J. Pharm. 37, 135-143.
97. Nio, Y. Imai, S. Ohgaki, M.H. and Tobe, T. (1988) Selective accumulation of a new antineoplastic agent, K-18 (human immunoglobulin conjugated melphalan), in Ehrlich carcinoma transplanted in mice. In Vivo 2, 177-188.
98. Zunino, F., Pratesi, G., and Pezzoni, G. (1987) Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug. Cancer Treat. Rep, 71, 367-373.
99. Trouet, A., Masquelier, M., Baurain, R., and Campeneere, D.D.-D. (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in V, V, studies. Proc. Natl. Acad. Sci. U.S.A. 79, 626-629.
100. Kohgo, Y. Nittsu, Y., Nishisato, T. Urushizaki, Y. Kondo, H., Fukushima, M., Tsushima, N., and Urushizaki, I. (1985) Transferrin receptors of tumor cells-potential tools for diagnosis and treatment of malignancies. In Proteins of iron storage and transport. (J. Spik, J. Montreuil, R. R. Crichton, and J. Mazurier, Eds.) pp 155-169, Elsevier Science Publishers,. V., Amsterdam.
101. Bogliolo, G., Muzzulini, C., Lerza, R., and Pannacciulli, I. Activity of doxorubicin linked to poly-L-asparatic acid on normal murine hematopoietic progenitor cells. Cancer Treat. Rep. 70, 1275-1281.
102. Poznansky, M. J., and Juliano, R. L. (1984) Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol.Rev. 36, 277-336.
103. Wallace, P. M. and Senter, P. D. (1991) In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2t, 349-352.
104. Melton, R. G., Searle, F., Sherwood, R. F. Bagshawe, M. H. D., and Bden, J. A. (1990) The potential of carboxypeptidase G2: Antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model. Br. J. Cancer 61, 420-424.
105. Bagshawe, K. D., Sharma, S. K., Springer, C. J., Antoniw, P., Boden, J. A., Rogers, G. T., Burke, P. J. Melton, R. G., and Sherwood, R. F. (1991) Antibody directed enzyme prodrug therapy (ADEPT): A clinical report. Dis. Markers 9, 233-238.
106. Vitetta, E. S. Stone, M. Amlot, P., Fay, J. May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thorpe, P. E. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51, 4052-4058.
107. Goldberg, J. A., Thomson, J. A. K. Brodnam, M. S. Fenner, J. Bessent, R. G., McKillop, J. H., Kerr, D. J. and McArdle, C. S. (1991) Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver métastasés. Br. J. Cancer 64, 114-119
108. Seymour, L. W. Flanagan, P. A. Al Shamkhani, A. Subr, V., Ulbrich, K.( Cassidy, J., and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies: Vehicles for tumour-targeted drug delivery. Select. Cancer Ther. 7, 5973.
109. Bartholeyns, J., and Moore, S. (1974) Pancreatic ribonuclease: enzymatic and physiological properties of a crosslinked dimer. Science 186, 444-445.
110. Buys, C. H. C. M., Dejong, A. S. H., Bouma, J. D. W., and Gruber, M. (1975) Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation. Biochim. Biophys. Acta 392, 95-100.
111. Ney, K. A., Gidwitz, S. and Pizzo, S. V. (1985) Binding and endocytosis of a2-macroglobulin-plasmin complex. Biochemistry 24, 4586-4592.